A high body mass index (BMI) is associated with increased cardiovascular risk. We sought to identify whether BMI influences the choice of lipid-lowering treatment in a large, real-world cohort of 52 916 patients treated with statins. The Dyslipidemia International Study (DYSIS) is a cross-sectional, observational, multicentre study in statin-treated patients ≥45 years of age from 30 countries; 1.1% were underweight (BMI < 18.5 kg/m 2 ), 33.1% had normal weight (BMI 18.5-24.9 kg/m 2 ), 41.5% were overweight (BMI 25-29.9 kg/m 2 ), 17.1% had class I obesity (BMI 30.0-34.9 kg/m 2 ), 5.0% had class II obesity .9 kg/m 2 ), and 2.1% had class III obesity (≥40 kg/m 2 ). BMI correlated with high-density lipoprotein cholesterol (HDL-C) and triglycerides (Spearman's ρ: −0.147 and 0.170, respectively; P < 0.0001 for both); however, there was no correlation with low-density lipoprotein cholesterol (LDL-C; ρ: 0.003; P = 0.51). Statin intensity increased with increasing BMI (ρ: 0.13; P < 0.001), an association that held after adjustment for comorbidities (OR: 2.4; 95% CI: 2.0-3.0) on BMI ≥ 30 kg/m 2 for atorvastatin equivalent However, there is little evidence that BMI contributes significantly to the decision-making process. These studies, however, did not evaluate the relationship between statin intensity and BMI.
| INTRODUCTION
A high body mass index (BMI) has been associated with increased cardiovascular risk and all-cause mortality. [1] [2] [3] [4] The relationship between BMI and individual serum lipid components has been evaluated in a number of studies. 5, 6 Lowering LDL-C is the focus of current guidelines for the treatment of dyslipidemia, with specific target levels for reducing cardiovascular risk provided for different risk groups. 7, 8 Statins form the backbone of lipid-lowering therapy (LLT) 8 ; however, it is not clear what factors influence their prescription in clinical practice. Various cardiovascular risk factors increase the likelihood of an individual being prescribed LLT, including hypertension and diabetes mellitus. 9, 10 However, there is little evidence that BMI contributes significantly to the decision-making process. These studies, however, did not evaluate the relationship between statin intensity and BMI.
In order to clarify the association of BMI with the levels of individual lipid components, and with prescribed statin intensity, we analyzed data from the global cohort of the Dyslipidemia International Study (DYSIS).
| MATERIALS AND METHODS

| Study design and patients
DYSIS is a cross-sectional, observational, multicentre study including statin-treated patients from 30 countries around the world. For this specific analysis we included all patients with the following parameters available: body weight and height, total cholesterol, LDL-C, HDL-C, and triglycerides. The study adhered to the Declaration of Helsinki.
| Data collection
Details of the LLT that each patient was receiving were noted. Administration was per discretion of the treating physician, and not influenced by the design of the study, which only documented the respective, administered dosages. Statin potency was normalized according to atorvastatin potency to allow comparisons among patients. 12 The most recent blood test was used to construct a full lipid profile, which included levels of LDL-C, HDL-C, total cholesterol, and triglycerides. LDL-C levels were measured in accordance with standard practice in the respective regions of the world. BMI was recorded on the date of the DYSIS data collection.
| Statistical methods
In order to identify correlations between BMI and LDL-C, HDL-C, and 3 | RESULTS
| Patients
A total of 52 916 statin-treated patients were enrolled. Of these, 1.18; 95% CI: 1.06-1.31). This is further indicated by the incremental increase in prevalence of these diseases at higher BMI levels ( Table 1) . 
Introduction of each of these diseases into
| DISCUSSION
BMI was found to correlate with HDL-C and triglycerides levels, but not with LDL-C. In addition, increased BMI was associated with the use of a higher statin dosage, independent of the presence of cardiovascular diseases. Ezetimibe use was more common in obese patients than in those patients with normal body weight.
In agreement with other studies, we found that increasing BMI correlated with decreasing HDL-C levels and increasing triglycerides levels. 5, 6, 14 On the other hand, we saw no such correlation between BMI and total cholesterol and, more importantly, LDL-C. 5 , 6 We would like to warn, though, that the DYSIS dataset may not be ideal for such a conclusion. All the patients included in the DYSIS project are statintreated, which results in the potential of interaction between the lipid-lowering treatment and its dose with the triglycerides, HDL-C, LDL-C and BMI. Based on the current data, we cannot exclude the possibility that there was no increase in LDL-C with BMI because of the effect of statin use and dosing. We are convinced that this is not the case, but the data are not suitable for dismissing this possibility.
Furthermore, we cannot exclude the potential role for concomitant drugs having an effect on BMI and/or LDL-C levels.
The importance of lowering LDL-C levels is undisputed, with studies demonstrating that it results in decreased rates of acute cardiovascular events. 7, 8 Indeed, this particular lipid is the main focus of current guidelines for the treatment of dyslipidemias. 7, 8 Statins and ezetimibe are the mainstays of LLT, having consistently been shown to reduce cardiovascular events in proportion to the absolute decrease in serum LDL-C concentration with PCSK9 inhibitors as novel therapies. 7, 15 In clinical practice, the presence of cardiovascular risk factors such as hypertension and diabetes mellitus increases the likelihood that an individual will be prescribed statin therapy. 9,10 A high BMI has also been linked to statin use. 10 However, these studies only reported whether or not a patient was taking a statin; they did not evaluate the intensity of therapy.
In the global population of patients included in DYSIS, we found that BMI positively correlated with atorvastatin equivalent daily statin dosage. This association was significant even after adjustment for the presence of ischemic heart disease, cerebrovascular disease, periph- are such examples to help identify patients who would benefit specifically from lipid-lowering treatment. 7, 8, 13 From this very large and representative cohort, it appears that physicians' decisions are directly influenced by patients' BMI when choosing statin dose or in combination with ezetimibe. Patients with higher BMI received higher doses of statins even after correcting for potential confounding factors such as diabetes or a history of ischemic heart disease. We therefore propose the use of established risk scores to guide clinical decision making in lipid-lowering therapy.
